Fabrication of paclitaxel hybrid nanomicelles to treat resistant breast cancer via oral administration

AIM: Oral chemotherapy using anticancer drugs would improve the clinical practice and the life quality of patients. The aim of the present study was to develop paclitaxel hybrid nanomicelles for oral administration to treat resistant breast cancer. METHODS: Evaluations were performed on human breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Dian, Ling-Hui, Hu, Ying-Jie, Lin, Jia-Ye, Zhang, Jing-Ying, Yan, Yan, Cui, Yi-Nuo, Su, Zhan-Bo, Lu, Wan-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799853/
https://www.ncbi.nlm.nih.gov/pubmed/29440897
http://dx.doi.org/10.2147/IJN.S150140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799853/
https://www.ncbi.nlm.nih.gov/pubmed/29440897
http://dx.doi.org/10.2147/IJN.S150140

Ejemplares similares